Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more
Forte Biosciences Inc (FBRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.166x
Based on the latest financial reports, Forte Biosciences Inc (FBRX) has a cash flow conversion efficiency ratio of -0.166x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.00 Million) by net assets ($84.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Forte Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Forte Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Forte Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SUZUKI
MU:SKI
|
N/A |
|
Bhakti Multi Artha Pt
JK:BHAT
|
-0.003x |
|
Laurent-Perrier
PA:LPE
|
0.002x |
|
Shandong Hongyu Agricultural Machinery Co Ltd
SHE:002890
|
-0.003x |
|
Xinjiang Haoyuan Natural Gas Co Ltd
SHE:002700
|
0.027x |
|
Zhejiang Oceanking Development Co Ltd
SHG:603213
|
0.067x |
|
ADCNF
OTCGREY:ADCNF
|
N/A |
|
Chunbo Co. Ltd
KQ:278280
|
0.015x |
Annual Cash Flow Conversion Efficiency for Forte Biosciences Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Forte Biosciences Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-30.75 Million | -0.586x | +27.93% |
| 2023-12-31 | $35.31 Million | $-28.71 Million | -0.813x | -285.51% |
| 2022-12-31 | $38.82 Million | $-8.19 Million | -0.211x | +47.47% |
| 2021-12-31 | $41.55 Million | $-16.68 Million | -0.401x | -28.50% |
| 2020-12-31 | $58.98 Million | $-18.42 Million | -0.312x | +35.23% |
| 2019-12-31 | $5.75 Million | $-2.77 Million | -0.482x | +18.65% |
| 2018-12-31 | $58.15 Million | $-34.47 Million | -0.593x | -35.35% |
| 2017-12-31 | $71.08 Million | $-31.13 Million | -0.438x | +89.63% |
| 2016-12-31 | $7.00 Million | $-29.54 Million | -4.222x | -684.24% |
| 2015-12-31 | $39.08 Million | $-21.04 Million | -0.538x | -- |